Delivery Order SPE2DB22D3301-SPE2DB25FY3VG
- Not listed
- The Defense Logistics Agency awarded a $31.8K delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of June 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,171.06 on April 22, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by April 23, 2025, and fulfillment based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $29,602.52 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, competitively awarded contract is not set-aside and carries an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $34,710.69. This firm fixed-price delivery order represents a non-set-aside competitive award and is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $48,759.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 6, 2025, with a completion date of August 7, 2025. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award through open procurement. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $37,029.83 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and is being fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,678.58 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY3VGDelivery Order
The Defense Logistics Agency (DLA) awarded a $30,081.66 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of April 25, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor contract running through December 2026 that supports military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The current delivery order for RINVOQ ER, a specialty pharmaceutical used in rheumatologic treatments, reflects AmerisourceBergen's role in fulfilling routine pharmaceutical supply needs for the military medical supply chain through its established prime vendor relationship with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.1k | 4/24/25 |